HopeStage
Back to all studies
CompletedNCT05164549

Comparing long-acting medicines for opioid recovery care

About this title

Extended-release Pharmacotherapy for Opioid Use Disorder

Read the official source — NCT05164549
Medication studyAges 18+United KingdomAddiction
The study in practice

Understand this study

Who was this study for?

Listed age limits: from 18 years.

Listed locations
Birmingham and 4 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: August 6, 2019
Recruitment status
Completed
Enrollment listed in the registry
342
Sponsor
King's College London
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United Kingdom
Age range
Over 18 Years
Official registry ID
NCT05164549
Official title
Show the full official title

Extended-release Pharmacotherapy for Opioid Use Disorder (EXPO): Protocol for an Open-label Randomised Controlled Trial of Injectable Maintenance Buprenorphine With Personalised Psychosocial Intervention.

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Birmingham · Dundee · London

2 more locations
  • Manchester
  • Newcastle upon Tyne

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is King's College London, a university.

Did this study involve medication?

Yes. The study involved medication, including Buprenorphine Injectable Product, Methadone and Buprenorphine.

Who was this study for?

Listed age limits: from 18 years.

Want to explore more studies?

Explore studies